5’-Ectonucleotidase (CD73) inhibitors: a patent review (2021-present)
Recent patents indicate a shift from maximizing enzymatic potency toward balanced optimization of potency, pharmacokinetics, and combinatorial compatibility. Perorally bioavailable small molecules and CD73-targeted imaging agents are positioning CD73 inhibition as a mature and versatile therapeutic and theranostic strategy.
Authors
- Anna K. Junker
- Zhaolin Wang
Institutions
- Siemens Healthineers (Germany) (DE)
Publication Details
- Journal
- Expert Opinion on Therapeutic Patents
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1080/13543776.2026.2638344
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00